Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington’s Disease to the United States, Canada and the United Kingdom
More than ten countries and more than twenty sites are now participating in the Company’s global pivotal trial for Huntington’s disease, with over 175 patients enrolled. SKY-0515’s Phase 1/2 enrollment is complete
